DEA Lawyers Cite Cannabis Safety Profile in Federal Rescheduling Hearings
Federal attorneys emphasize marijuana's medical benefits and lower risk profile versus alcohol and opioids in administrative proceedings that could reshape industry regulation.
Federal rescheduling hearings commenced this week with Drug Enforcement Administration attorneys presenting testimony that underscores cannabis's medical utility and favorable safety profile compared to alcohol and opioids. The administrative proceedings represent the most significant federal cannabis policy development since the Controlled Substances Act's inception, with potential implications for the entire $30 billion U.S. cannabis market.
The DEA's acknowledgment of marijuana's relative safety marks a notable shift in federal positioning. Agency lawyers highlighted scientific evidence demonstrating cannabis poses lower addiction potential and overdose risk than Schedule I and II substances currently regulated under federal law. This testimony aligns with Food and Drug Administration assessments that supported the rescheduling recommendation, creating regulatory momentum that could accelerate policy changes.
A successful rescheduling to Schedule III would eliminate the 280E tax burden that currently prevents cannabis operators from deducting standard business expenses. Multi-state operators like Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF) could see immediate margin expansion, with some analysts projecting 15-20% increases in effective tax rates. The change would also facilitate interstate commerce and banking relationships that remain restricted under current federal prohibition.
The hearing's closed-door format limits public visibility into specific arguments and timelines, though industry observers expect proceedings to continue through early 2025. Federal rescheduling would not immediately legalize recreational cannabis but would create a framework for regulated medical access nationwide. This development could pressure remaining prohibition states to establish medical programs while providing existing operators with expanded market opportunities.
Cannabis equity markets have already priced in substantial rescheduling expectations, with the AdvisorShares Pure US Cannabis ETF (MSOS) gaining over 40% since initial rescheduling announcements. However, the administrative process remains subject to political and legal challenges that could delay implementation. The industry now awaits additional hearing developments that will determine whether federal policy finally aligns with the scientific consensus on cannabis safety and medical efficacy.